PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Changes in Voice Patterns for Monitoring Volume Status (Cardio)

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

Secubitirl-Valsartan Across the Spectrum of EFs

DCD - Donation After Cadiac Death

Innovations in LVAD Therapies

Use of Transthoracic Radar Monitoring for Assessing Volume Status (Sensible Medical)

Reverse Remodeling in Heart Failure

Physiological Rationale and Devices for Interatrial Shunts